Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq ® , a New Generation Recombinant FVIII of Human Origin

Blood (2016) 128 (22): 327.

https://doi.org/10.1182/blood.V128.22.327.327

Published: 2016

Journal Articles

Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors)

Manuel Carcao, MD, Maria L. Avila, MD, Victor S. Blanchette, MD FRCP, Elena Santagostino, MD PhD, Carmen Escuriola-Ettingshausen, MD PhD, Cindy A. Leissinger, MD, Thierry Lambert, Louis M. Aledort, MD

Blood (2015) 126 (23): 3535.

https://doi.org/10.1182/blood.V126.23.3535.3535

Published: 2015

Journal Articles

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A

Jenny Goudemand, Chantal Rothschild, Virginie Demiguel, Christine Vinciguerrat, Thierry Lambert, Hervé Chambost, Annie Borel-Derlon, Ségolène Claeyssens, Yves Laurian, Thierry Calvez, the members of the FVIII-LFB and Recombinant FVIII study groups

Blood (2006) 107 (1): 46–51.

https://doi.org/10.1182/blood-2005-04-1371

Published: 2006

Journal Articles

Immune Tolerance Resulting in a Dramatic Clinical Improvement in a High-Responding Inhibitor Hemophilia A Patient Using Immunosuppression with Mycofenolate Mofetil and a Factor VIII Concentrate Containing Von Willebrand Factor.

Thierry Lambert, MD, Cécile Goujard, MD, Anne Rafowicz, MD, Benoît Guillet, MD, Yacine Taoufik, MD, Marie Dreyfus

Blood (2005) 106 (11): 3220.

https://doi.org/10.1182/blood.V106.11.3220.3220

Published: 2005

Journal Articles

A New Formulation of Recombinant Human Factor IX Is Bioequivalent to BeneFIX: A Double-Blind, Randomized, Crossover Pharmacokinetic and Open-Label Safety and Efficacy Study.

Jerry Sherman Powell, MD, Thierry Lambert, MD, F. Hernández Navarro, MD, Michael Recht, MD, Sharon T. Sullivan, PhD, Chandrasekhar Udata, PhD, Leslie C. Lilly, BSN, RN, David A. Roth, MD, The rFIX-R Study Group

Blood (2005) 106 (11): 4076.

https://doi.org/10.1182/blood.V106.11.4076.4076

Published: 2005

Journal Articles

FranceCoag Network: A National Multicenter Prospective Cohort for Congenital Bleeding Disorders.

Edith Fressinaud, Jocelyne Dieval, Valerie Gay, Viviane Guerin, Thierry Lambert, Jean Donadieu, Reseau FranceCoag

Blood (2005) 106 (11): 4094.

https://doi.org/10.1182/blood.V106.11.4094.4094

Published: 2005

Journal Articles

FVIII Recovery after a Single Infusion of Recalibrated ReFacto in 14 Severe Hemophilia A Patients.

Thierry Lambert, MD, Claude Guérois, MD, Valerie Gay, MD, Natalie Stieltjes, MD, Marie-Anne Bertrand, MD, Annie Derlon, MD, Marianne Sigaud, MD, Abel Hassoun, MD, Claude Négrier, MD, Brigitte Coatmelec, MD, Marie Dreyfus, MD, Arnaud Dubanchet, MD

Blood (2005) 106 (11): 2143.

https://doi.org/10.1182/blood.V106.11.2143.2143

Published: 2005

Journal Articles

Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A

Ton Lisman, Laurent O. Mosnier, Thierry Lambert, Evelien P. Mauser-Bunschoten, Joost C. M. Meijers, H. Karel Nieuwenhuis, Philip G. de Groot

Blood (2002) 99 (1): 175–179.

https://doi.org/10.1182/blood.V99.1.175

Published: 2002

NARROW

Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq ® , a New Generation Recombinant FVIII of Human Origin

Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors)

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A

Immune Tolerance Resulting in a Dramatic Clinical Improvement in a High-Responding Inhibitor Hemophilia A Patient Using Immunosuppression with Mycofenolate Mofetil and a Factor VIII Concentrate Containing Von Willebrand Factor.

A New Formulation of Recombinant Human Factor IX Is Bioequivalent to BeneFIX: A Double-Blind, Randomized, Crossover Pharmacokinetic and Open-Label Safety and Efficacy Study.

FranceCoag Network: A National Multicenter Prospective Cohort for Congenital Bleeding Disorders.

FVIII Recovery after a Single Infusion of Recalibrated ReFacto in 14 Severe Hemophilia A Patients.

Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only